Dow Today: Pfizer (PFE) Higher

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

The Dow Jones Industrial Average ( ^DJI) is trading up 35 points (+0.3%) at 12,577 as of Friday, Nov 16, 2012, 1:35 p.m. ET. During this time, 508.8 million shares of the 30 Dow components have changed hands vs. an average daily trading volume of 602.7 million. The NYSE advances/declines ratio sits at 1,936 issues advancing vs. 1,066 declining with 81 unchanged.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

The Dow component leading the way higher looks to be Pfizer (NYSE: PFE), which is sporting an 11-cent gain (+0.5%) bringing the stock to $23.77. This single gain is lifting the Dow Jones Industrial Average by 0.83 points or roughly accounting for 2.4% of the Dow's overall gain. Volume for Pfizer currently sits at 29 million shares traded vs. an average daily trading volume of 27.2 million shares.

Pfizer has a market cap of $175.3 billion and is part of the health care sector and drugs industry. Shares are up 10% year to date as of Thursday's close. The stock's dividend yield sits at 3.7%.

Pfizer Inc., a biopharmaceutical company, engages in the discovery, development, manufacture, and sale of medicines for people and animals worldwide. The company has a P/E ratio of 18.5, above the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

FREE for a limited time only: Get TheStreet Ratings #1 Stock Report NOW!.
null

If you liked this article you might like

The 6 Medications Being Used to Tackle the Opioid Epidemic

Allergan's Restasis Patent Transfer to Face Precedent-Setting Legal Battle

Friday Selloff May Be On Its Way; Tenet Gears Up for Sale -- ICYMI

Dow Posts Fresh Record, Third in a Row, but S&P 500 and Nasdaq Fall